PASSAGE BIO INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
PASSAGE BIO INC. - More news...
PASSAGE BIO INC. - More news...
- Passage Bio to Participate in Upcoming Investor Conferences
- Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
- Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
- Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award
- Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
- Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Cowen 43rd Annual Health Care Conference
- Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
- Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
- Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
- Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
- Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
- Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
- Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
- Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference
- Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations
- Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference
- Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
- Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors
- Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
- Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy
- Passage Bio Announces Leadership Transition
